France
· Delayed Price · Currency is EUR Theraclion Statistics
Total Valuation
Theraclion has a market cap or net worth of EUR 15.28 million. The enterprise value is 17.29 million.
| Market Cap | 15.28M |
| Enterprise Value | 17.29M |
Important Dates
The next estimated earnings date is Friday, December 27, 2024.
| Earnings Date | Dec 27, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Theraclion has 46.03 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 46.03M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 12.51% |
| Owned by Institutions (%) | 10.12% |
| Float | 31.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 6.56 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.85 |
| EV / Sales | 13.48 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -6.54 |
Financial Position
The company has a current ratio of 4.82, with a Debt / Equity ratio of 2.41.
| Current Ratio | 4.82 |
| Quick Ratio | 3.50 |
| Debt / Equity | 2.41 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.99 |
| Interest Coverage | -121.92 |
Financial Efficiency
Return on equity (ROE) is -72.43% and return on invested capital (ROIC) is -14.09%.
| Return on Equity (ROE) | -72.43% |
| Return on Assets (ROA) | -10.36% |
| Return on Capital (ROIC) | -14.09% |
| Revenue Per Employee | 45,816 |
| Profits Per Employee | -127,222 |
| Employee Count | 29 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 0.99 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -14.11% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -14.11% |
| 50-Day Moving Average | 0.37 |
| 200-Day Moving Average | 0.36 |
| Relative Strength Index (RSI) | 38.93 |
| Average Volume (20 Days) | 18,272 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Theraclion had revenue of EUR 1.28 million and -3.56 million in losses.
| Revenue | 1.28M |
| Gross Profit | -1.78M |
| Operating Income | -2.96M |
| Pretax Income | -4.63M |
| Net Income | -3.56M |
| EBITDA | -3.28M |
| EBIT | -2.96M |
| Earnings Per Share (EPS) | n/a |
Balance Sheet
The company has 5.90 million in cash and 7.91 million in debt, giving a net cash position of -2.01 million or -0.04 per share.
| Cash & Cash Equivalents | 5.90M |
| Total Debt | 7.91M |
| Net Cash | -2.01M |
| Net Cash Per Share | -0.04 |
| Equity (Book Value) | 3.28M |
| Book Value Per Share | n/a |
| Working Capital | 9.81M |
Cash Flow
In the last 12 months, operating cash flow was -2.57 million and capital expenditures -77,692, giving a free cash flow of -2.65 million.
| Operating Cash Flow | -2.57M |
| Capital Expenditures | -77,692 |
| Free Cash Flow | -2.65M |
| FCF Per Share | -0.06 |
Margins
Gross margin is -139.01%, with operating and profit margins of -230.85% and -277.68%.
| Gross Margin | -139.01% |
| Operating Margin | -230.85% |
| Pretax Margin | -361.07% |
| Profit Margin | -277.68% |
| EBITDA Margin | -255.29% |
| EBIT Margin | -230.85% |
| FCF Margin | n/a |
Dividends & Yields
Theraclion does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | n/a |
| FCF Yield | -17.32% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Theraclion has an Altman Z-Score of 1.06. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.06 |
| Piotroski F-Score | n/a |